Cardiovascular Diseases, Cardiovascular Risk Factor, Testicular Cancer
Conditions
Brief summary
Chemotherapy drugs improve cancer survival but increase the risk of cardiovascular disease (CVD). VEGF inhibitors (VEGFI) cause severe hypertension, while cisplatin appears pro-thrombotic. Hence while cancer survival may improve, this is at the risk of potentially severe CVD and associated morbidity. Mechanisms underlying the cardiovascular toxicities of VEGFI and cisplatin are unknown, but effects on vascular function may be important. The INTELLECT study will phenotype the endothelial effects of VEGFI and cisplatin using a variety of methods.
Detailed description
There remains an unmet need to identify a preventive treatment for patients with testicular cancer treated with platinum based chemotherapy to diminish the risk of subsequent cardiovascular events. A future randomised trial of statin therapy in these patients is under consideration and results from this study will inform its design. The information gained from this pilot study will guide the development of interventional pharmacological studies that are directed towards the most appropriate pathophysiological processes, at the most appropriate time and in the most appropriate patient groups treated with platinum based chemotherapy for testicular cancer.
Interventions
None listed
Sponsors
University of Glasgow
NHS Greater Glasgow and Clyde
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Histological diagnosis of stage 1 low-risk germ cell testicular cancer treated with orchidectomy, or IGCCC good or intermediate prognosis metastatic testicular/retroperitoneal germ cell cancer treated with orchidectomy (and or retroperitoneal surgery) plus cisplatin based chemotherapy, 12 - 18 months or 5 - 7 years previously. * Aged between 18 and 50 years inclusive, at time of enrolment
Exclusion criteria
* Unable to provide written, informed consent * Unable or unwilling to attend for investigations * Current active involvement in a clinical trial * Those receiving drug treatment for any vascular disease: o Including hypertension, hyperlipidaemia, cerebrovascular disease, ischaemic heart disease or heart failure * Asthma * Chronic obstructive pulmonary disease * Diabetes mellitus * Arial fibrillation/flutter * Oral anticoagulation therapy * Cigarette smoker or tobacco use * Recreational drug use * Ongoing inflammatory, infective or autoimmune disease * Other malignant disease diagnosed in previous 7 years * Previous venous or arterial thrombotic/thromboembolic event
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| venous occlusion plethysmography assessment of endothelial function | 8 weeks | expressed as ml per 100 ml of forearm volume per minute |
Countries
United Kingdom
Outcome results
None listed